GLPwatch
Mounjaro for Obstructive sleep apnea
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for obstructive sleep apnea, and any use for this condition is off-label or investigational. Research listed includes studies exploring tirzepatide's potential impact on obstructive sleep apnea, such as weight loss and cardiometabolic risk reduction, but no efficacy claims are made beyond the studies themselves.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Obstructive sleep apnea |
| Approval status | Investigational / off-label |
| Research papers | 18 |
Mounjaro is not FDA-approved for obstructive sleep apnea; the research below reflects investigational or off-label study only.
Research on tirzepatide for obstructive sleep apnea (18)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Clinical Impact of Tirzepatide on Patients With OSA and Obesity.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
- Comparative clinical outcomes of adults with obstructive sleep apnea and comorbid obesity receiving tirzepatide versus bariatric metabolic surgery: A Multi-Institutional propensity score matched study.
- Tirzepatide gains US Food and Drug Administration approval for the management of obstructive sleep apnea: Implications for oral health care providers.
- Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.
- Tirzepatide-induced weight loss and obstructive sleep apnea improvement in an adult with type 2 diabetes: A case report.
- Tirzepatide (Zepbound) for obstructive sleep apnea.
- [Progress on tirzepatide, a GIP/GLP-1 receptor agonist, for the treatment of obesity-related obstructive sleep apnea].
- Exploring the cardiopulmonary effects of tirzepatide in atrial fibrillation and comorbid chronic obstructive pulmonary disease.
- Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.
- [SURMOUNT-OSA study : tirzepatide improves obstructive sleep apnoea in patients with obesity].
- Semaglutide and Tirzepatide for the Treatment of Obesity and Weight-Related Comorbidities: A Narrative Review.
- Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.